A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination With Docetaxel in Participants With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Latest Information Update: 13 May 2025
At a glance
- Drugs PRT 3789 (Primary) ; Docetaxel
- Indications Advanced breast cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Prelude Therapeutics
Most Recent Events
- 06 May 2025 According to a Prelude Therapeutics media release, Updated data from the trial is expected to be presented at a major medical meeting in the second half of 2025.
- 06 May 2025 According to a Prelude Therapeutics media release, The company has completed enrollment of monotherapy dose escalation at the 665 mg once weekly IV dose and has selected 500 mg once weekly as the recommended Phase 2 dose with docetaxel and is nearing completion of backfill cohorts.
- 10 Mar 2025 Interim results presented in a Prelude Therapeutics media release